Andrea Lobo, PhD, science writer —

Andrea Lobo holds a PhD in cell biology/neurosciences from the University of Coimbra-Portugal, where she studied stroke biology. As a research scientist for 19 years, Andrea participated in academic projects in multiple research fields, including stroke, gene regulation, cancer, and rare diseases. She has authored multiple research papers in peer-reviewed journals.

Articles by Andrea Lobo

January 16, 2023 News by Andrea Lobo, PhD

Samples From ALS Patients in Phase 3 NurOwn Trial Open to Researchers

Biological samples from amyotrophic lateral sclerosis (ALS) patients who took part in the Phase 3 clinical trial of NurOwn, a cell-based therapy, are being donated by BrainStorm Cell Therapeutics to a repository for use by the research community. The samples include blood and spinal fluid (cerebrospinal fluid or CSF)…

December 21, 2022 News by Andrea Lobo, PhD

Trial of QRL-201, Aiming to Slow ALS Progression, Opening in Canada

Health Canada has given a green light to QurAlis‘ request to open a Phase 1 clinical trial of QRL-201, its candidate antisense oligonucleotide (ASO) molecule to protect and repair nerve cells, slowing disease progression, in people with amyotrophic lateral sclerosis (ALS). The global trial, called ANQUR (NCT05633459), will…

Subscribe to our newsletter

Get regular updates to your inbox.

Andrea Lobo, PhD, science writer —

Articles by Andrea Lobo

Samples From ALS Patients in Phase 3 NurOwn Trial Open to Researchers

Trial of QRL-201, Aiming to Slow ALS Progression, Opening in Canada

Recent Posts

Subscribe to our newsletter